Kite Pharma, Inc.
KITE
KITE was delisted on the 2nd of October, 2017.
209 hedge funds and large institutions have $3.81B invested in Kite Pharma, Inc. in 2017 Q1 according to their latest regulatory filings, with 48 funds opening new positions, 72 increasing their positions, 72 reducing their positions, and 16 closing their positions.
200% more first-time investments, than exits
New positions opened: 48 | Existing positions closed: 16
90% more capital invested
Capital invested by funds: $2B → $3.81B (+$1.81B)
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
14% more funds holding
Funds holding: 184 → 209 (+25)
9% more call options, than puts
Call options by funds: $56.3M | Put options by funds: $51.5M
0% more repeat investments, than reductions
Existing positions increased: 72 | Existing positions reduced: 72
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$224M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$103M |
| 3 |
Capital Research Global Investors
Los Angeles,
California
|
+$42.9M |
| 4 |
Capital World Investors
Los Angeles,
California
|
+$36.6M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$35.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$35.3M |
| 2 |
State Street
Boston,
Massachusetts
|
-$28.7M |
| 3 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
-$21.2M |
| 4 |
HCM
Highline Capital Management
New York
|
-$19.4M |
| 5 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$19.1M |
KITE Hedge Fund Activity: Q1 2017 in Review
209 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Kite Pharma, Inc. (KITE) for Q1 2017, worth a combined $3.81B — up 90% from $2B a quarter earlier.
Buyers outnumbered sellers: 48 funds opened new KITE positions and 16 closed out — a net gain of 32 holders — while 72 added to existing stakes and 72 trimmed.
The largest buyer was BlackRock, adding an estimated $224M. The largest seller was JP Morgan Chase, cutting an estimated $35.3M.
- 209 institutional investors held Kite Pharma, Inc. (KITE) as of Q1 2017, up from 184 in Q4 2016.
- Funds reported $3.81B of Kite Pharma, Inc. stock for Q1 2017, up 90% quarter-over-quarter.
- 48 funds opened new Kite Pharma, Inc. positions in Q1 2017 and 16 closed out, a net change of +32 holders.
- The largest Kite Pharma, Inc. buyer in Q1 2017 was BlackRock, an estimated $224M added.
- The largest Kite Pharma, Inc. seller in Q1 2017 was JP Morgan Chase, an estimated $35.3M sold.
Based on aggregated 13F filings for Q1 2017.